| Original language | English (US) |
|---|---|
| Pages (from-to) | 184-185 |
| Number of pages | 2 |
| Journal | Journal of Diabetes Science and Technology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2020 |
Keywords
- artificial pancreas
- automated insulin delivery
- glucose variability
- hyperglycemia
- stress
- type 1 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Bioengineering
- Biomedical Engineering
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Diabetes Science and Technology, Vol. 15, No. 1, 2020, p. 184-185.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Use of the Interoperable Artificial Pancreas System for Type 1 Diabetes Management During Psychological Stress
AU - Pinsker, Jordan E.
AU - Deshpande, Sunil
AU - McCrady-Spitzer, Shelly
AU - Church, Mei Mei
AU - Kaur, Ravinder Jeet
AU - Perez, Jimena
AU - Desjardins, Donna
AU - Piper, Molly
AU - Reid, Corey
AU - Doyle, Francis J.
AU - Kudva, Yogish C.
AU - Dassau, Eyal
N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JEP reports receiving grant support, provided to his institution, consulting fees, and speaker fees from Tandem Diabetes Care, Inc.; grant support, provided to his institution, and advisory board fees from Medtronic; grant support, provided to his institution, and consulting fees from Eli Lilly; grant support and supplies, provided to his institution, from Insulet; and supplies, provided to his institution, from Dexcom, Inc. FJD reports product support from Dexcom, Inc., and Tandem Diabetes Care, as well as patent royalties from Insulet Inc., Dexcom, Mode AGC, and Roche, and is a Scientific Advisor to Mode AGC. YCK has received product support from Dexcom and Roche Diabetes, and consulted for Novo Nordisk. ED is currently an employee of Eli Lilly and Company. The work presented in this paper was performed as part of ED’s academic appointment and is independent of his employment with Eli Lilly and Company. ED reports consulting fees from Eli Lilly, speaker bureau fees from Roche Diabetes Care, and product support from Dexcom, Inc. and Tandem Diabetes Care, as well as patent royalties from Insulet Inc., Dexcom, Mode AGC, and Roche. No conflicts of interest relevant to this project are reported for the rest of the authors. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was made possible through collaboration between the JDRF and The Leona M. and Harry B. Helmsley Charitable Trust (2-SRA-2017-503-M-B) and by grants from the National Institutes of Health (DP3DK104057 and DP3DK113511). Product support was provided by Dexcom Inc. (research discount on CGM sensors, with transmitters provided in-kind) (IIS-2019-017). Tandem t:AP insulin pumps were purchased from Tandem Diabetes Care, Inc. at full price. The funders and device manufacturers had no influence on the design or conduct of the trial and were not involved in data collection or analysis, the writing of the manuscript, or the decision to submit it for publication.
PY - 2020
Y1 - 2020
KW - artificial pancreas
KW - automated insulin delivery
KW - glucose variability
KW - hyperglycemia
KW - stress
KW - type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85089392430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089392430&partnerID=8YFLogxK
U2 - 10.1177/1932296820948566
DO - 10.1177/1932296820948566
M3 - Letter
C2 - 32783473
AN - SCOPUS:85089392430
SN - 1932-2968
VL - 15
SP - 184
EP - 185
JO - Journal of Diabetes Science and Technology
JF - Journal of Diabetes Science and Technology
IS - 1
ER -